Physician profile
Kaitlyn Smith
NPI 1598306037
$5,177.38
in general payments reported to CMS, 2019-2025
27 companies · $81.13 in 2025
The $81.13 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,286 · 2022: $1,774 · 2023: $36.92 · 2025: $81.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $722.32 | 2021-2022 | |
| Lilly USA, LLC | $649.81 | 2021-2022 | |
| Medtronic, INC. | $386.64 | 2021-2025 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.41 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $317.46 | 2021-2022 | |
| Amarin Pharma, INC. | $241.22 | 2021 | |
| Dexcom, INC. | $180.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $166.75 | 2021-2022 | |
| Abbott Laboratories | $155.25 | 2021-2025 | Eterna, Proclaim |
| Esperion Therapeutics, INC. | $152.66 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $142.74 | 2021-2022 | |
| Becton, Dickinson and Company | $142.46 | 2022 | |
| Amgen INC. | $132.89 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.45 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $62.57 | 2021-2022 | |
| Grt US Holding, INC. | $54.04 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $52.95 | 2022 | |
| Insulet Corporation | $52.35 | 2021-2022 | |
| Rochester Medical Corporation | $48.60 | 2021 | |
| Vifor Pharma, INC. | $40.48 | 2021-2022 | |
| Pfizer INC. | $36.44 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $34.39 | 2021-2022 | |
| Corcept Therapeutics | $19.17 | 2021 | |
| Si-Bone, INC. | $15.91 | 2022 | |
| Tandem Diabetes Care, INC. | $15.57 | 2021 | |
| Averitas Pharma INC. | $15.41 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.